253 related articles for article (PubMed ID: 28735365)
1. An Update on the Use of Immunotherapy in the Treatment of Lymphoma.
Marron TU; Kalac M; Brody J
Curr Hematol Malig Rep; 2017 Aug; 12(4):282-289. PubMed ID: 28735365
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
3. Cancer immune therapy for lymphoid malignancies: recent advances.
Klausen U; Jørgensen NGD; Grauslund JH; Holmström MO; Andersen MH
Semin Immunopathol; 2019 Jan; 41(1):111-124. PubMed ID: 30006739
[TBL] [Abstract][Full Text] [Related]
4. Emerging immunotherapy in pediatric lymphoma.
Erker C; Harker-Murray P; Burke MJ
Future Oncol; 2016 Jan; 12(2):257-70. PubMed ID: 26616565
[TBL] [Abstract][Full Text] [Related]
5. Novel immunotherapies in lymphoid malignancies.
Batlevi CL; Matsuki E; Brentjens RJ; Younes A
Nat Rev Clin Oncol; 2016 Jan; 13(1):25-40. PubMed ID: 26525683
[TBL] [Abstract][Full Text] [Related]
6. [Lymphomas: A therapeutic update].
Wolfromm A; Delarue R
Rev Med Interne; 2017 Oct; 38(10):685-690. PubMed ID: 28958786
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies in indolent B-cell lymphomas.
Radhakrishnan VS; Davies AJ
Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
[TBL] [Abstract][Full Text] [Related]
8. New Immunotherapy Strategies in Breast Cancer.
Yu LY; Tang J; Zhang CM; Zeng WJ; Yan H; Li MP; Chen XP
Int J Environ Res Public Health; 2017 Jan; 14(1):. PubMed ID: 28085094
[TBL] [Abstract][Full Text] [Related]
9. Active and passive immunotherapy for lymphoma: proving principles and improving results.
Brody J; Kohrt H; Marabelle A; Levy R
J Clin Oncol; 2011 May; 29(14):1864-75. PubMed ID: 21482977
[TBL] [Abstract][Full Text] [Related]
10. Current targeted therapies in lymphomas.
Chung C
Am J Health Syst Pharm; 2019 Oct; 76(22):1825-1834. PubMed ID: 31580408
[TBL] [Abstract][Full Text] [Related]
11. [Development of monoclonal antibody therapy for malignant lymphoma].
Ogura M
Nihon Rinsho; 2002 Mar; 60(3):505-16. PubMed ID: 11904966
[TBL] [Abstract][Full Text] [Related]
12. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
14. Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.
Smits NC; Sentman CL
J Clin Oncol; 2016 Apr; 34(10):1131-3. PubMed ID: 26884583
[No Abstract] [Full Text] [Related]
15. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
Sikaria S; Aldoss I; Akhtari M
Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of lymphoma: update and review of the literature.
Berdeja JG
Curr Opin Oncol; 2003 Sep; 15(5):363-70. PubMed ID: 12960517
[TBL] [Abstract][Full Text] [Related]
17. T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances.
Yu L; Wang J
J Cancer Res Clin Oncol; 2019 Apr; 145(4):941-956. PubMed ID: 30798356
[TBL] [Abstract][Full Text] [Related]
18. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody therapies for lymphomas.
Foon KA
Cancer J; 2000; 6(5):273-8. PubMed ID: 11079163
[TBL] [Abstract][Full Text] [Related]
20. [Innovative antibody-therapies for malignant lymphomas].
Müller AM; Rawluk J; Thierry V; Brink I; Engelhardt M
Dtsch Med Wochenschr; 2005 Dec; 130(48):2783-8. PubMed ID: 16307409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
